M&G Plc
Institutional investor · Portfolio as of Q1 2024
Top Holdings366 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
| 263,193 | $5.8B | 21.7% | — | — | 1 qtr | New 98 | |
| 1.7M | $2.1B | 7.8% | — | — | 1 qtr | New 98 | |
| 5.9M | $2B | 7.6% | — | — | — | New 98 | |
BURFORD CAPITAL LIMITED | 1.1M | $1.8B | 6.7% | $15.75 | 0.00% | 1 qtr | New 98 |
MICROSOFT CORP | 2M | $846.1M | 3.2% | $415.31 | 0.00% | 1 qtr | New 88 |
METHANEX CORP | 13.1M | $589.5M | 2.2% | $43.22 | 0.00% | 1 qtr | New 81 |
BROADCOM INC | 444,364 | $588.8M | 2.2% | $129.68 | 0.00% | 1 qtr | New 81 |
BRISTOL-MYERS SQUIBB CO | 7.3M | $392.6M | 1.5% | $48.12 | 0.00% | 1 qtr | New 71 |
ALPHABET INC-CL A | 2.2M | $332M | 1.3% | $149.80 | 0.00% | 1 qtr | New 71 |
VISA INC-CLASS A SHARES | 1.2M | $327.8M | 1.2% | $273.88 | 0.00% | 1 qtr | New 71 |
NEXTERA ENERGY INC | 4.7M | $303.1M | 1.1% | — | — | — | — |
MEDTRONIC PLC | 3M | $259.2M | 1.0% | $82.98 | 0.00% | 1 qtr | New 60 |
INDIVIOR PHARMACEUTICALS INC USD0.50 Shares | 117,546 | $251.4M | 0.9% | $21.42 | 0.00% | 1 qtr | New 60 |
META PLATFORMS INC-CLASS A | 503,874 | $244.9M | 0.9% | $482.72 | 0.00% | 1 qtr | New 60 |
UNITEDHEALTH GROUP INC | 484,269 | $239.7M | 0.9% | $477.24 | 0.00% | 1 qtr | New 60 |
CROWN CASTLE INTL CORP | 2.1M | $221.6M | 0.8% | $96.22 | 0.00% | 1 qtr | New 60 |
FRANCO-NEVADA CORP /CAD/ | 1.8M | $220M | 0.8% | $117.52 | 0.00% | 1 qtr | New 60 |
LOWE'S COS INC | 854,881 | $218M | 0.8% | $242.52 | 0.00% | 1 qtr | New 60 |
ALEXANDRIA REAL ESTATE EQUIT | 1.6M | $204M | 0.8% | $116.86 | 0.00% | 1 qtr | New 60 |
ANTHEM INC | 391,886 | $203.4M | 0.8% | $503.58 | 0.00% | 1 qtr | New 60 |
M&G Plc manages $26.5B across 366 positions as of Q1 2024. Top holdings: FERGL (21.7%), DECL (7.8%), INTERDIGITAL INC (7.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 366 new positions, 0 exits, 0 increased. Top move: FERGL (NEW, conviction 98). Portfolio: $26.5B across 366 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer